Our patient’s clinical presentation, tumor size, inconclusive catecholamines and ACTH laboratory studies, and biochemical evidence of primary hyperaldosteronism compounded the diagnostic and management dilemma. The gene discussed is POMC; the disease is Primary hyperaldosteronism.